These treatments are aimed at specific, especially genetic changes of the malignant cells. Different NSCLC subtypes are associated with potentially targetable biomarker such as epidermal growth factor receptor (EGFR) mutations [8], [9], [10], [11] and [12] – KRAS mutations [13] – echinoderm microtubule – associated protein like 4 (EML4), anaplastic lymphoma kinase (ALK) or fusion PD173074 order genes (EML4–ALK) [14] and [15] and c-MET over expression

or amplification [16], [17], [18] and [19]. Our hope is to apply the knowledge of the treatments with targeted agents acquired in advanced stages of NSCLC to the earlier stages of NSCLC, too, thus being able to increase the NSCLC cure-rate. Combining different targeted agents or sequencing them properly will be very important in the new era of targeted individualized therapy. In this publication, we will describe the importance of a team work from obtaining the tumor tissue, pathological diagnosis, molecular analysis, staging of the disease, the different treatments all the MEK inhibitor way

to supportive care. You will learn about the different interventional procedures in order to obtain a satisfactory tumor specimen for analysis by pathologist and molecular biologists, to radiation and medical oncologist’s treatments and ending with supportive care of patients. By this, we hope to give a complete review and guidelines for present and future approach to NSCLC patients. “
“EVIDENCE LEVELS: The following evidence levels (EL) were adopted for these guidelines:  • (EL-1) High Level: well conducted phase III randomized studies or well done meta-analyses.

see more  • (EL-2) Intermediate Level: good phase II data or phase III trials with limitations.  • (EL-3) Low Level: observational or retrospectives studies expert opinions. Full-size table Table options View in workspace Download as CSV !!!FRAG!!! I. ALL LUNG CANCER PATIENTS  1.1 INITIAL PATIENT ASSESSMENT   1.1.1 Perform history and physical examination, and document smoking history and performance status.   1.1.2 Perform the following laboratory tests: Complete blood count (CBC), differential, liver function test (LFT), renal function, electrolytes, calcium, serum albumin, magnesium and phosphorus.   1.1.3 Two-view chest X-ray.  1.2 DIAGNOSIS   1.2.1 Obtain adequate tissue specimen for diagnostic and predictive markers.   1.2.2 Confirm histopathological diagnosis of lung cancer and determine the histological subtypes of non-small cell lung cancer i.e. adeno carcinoma vs squamous cell vs large cell carcinoma using most recent pathological classification of lung cancer. Utilization of proper immuno histochemistry staining (minimal panel to include CK 5/6, CK 7, CK 20, TTF 1 and P63) to minimize the diagnosis of not otherwise specified (NOS).   1.2.